HEART FAILURE (HF)
For pulmonary artery pressure monitoring
Abbott’s CardioMEMS™ HF System is the leading remote monitoring platform for both heart failure with preserved ejection fraction (HFpEF)1 and heart failure with reduced ejection fraction (HFrEF) patients clinically proven to:
Aid physicians in preventing worsening heart failure2
Reduces heart failure hospitalizations and re-admissions3
quality of life4
As telemedicine becomes more common, the CardioMEMS HF System is a safe, reliable way to help your patients manage their heart failure.
The CardioMEMS HF System offers you real-time notification of patient changes and simple, convenient access to secure data for proactive, personalized patient management. It also provides patients with a heightened awareness of the factors affecting their health and a powerful sense of control.
The CardioMEMS HF System remotely monitors changes in PA pressure, an early indicator of the onset of worsening heart failure. These early changes can often be addressed through simple adjustments to care, such as titration of medications, most often without requiring an appointment with the patient.
Traditionally, clinicians have focused on physiological markers (patient weight, blood pressure, etc.) to detect worsening heart failure. Unfortunately, these markers appear late in the time course of decompensation.
Relying on them leaves little time to respond before hospitalization is necessary.
The CardioMEMS HF System is proven through clinical trial data to reduce heart failure hospitalizations and mortality,2,3 as well as improve quality of life (QoL) for HFrEF and HFpEF patients.3,4,5 The actionable measurements of PA pressures allow for proactive changes in medical therapy before heart failure symptoms appear.1 The ability to individually set patient thresholds allows physicians to personalize and optimize care and medical management for each patient.
ESC 2023 HF Satellite Symposium
- Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014;7(6):935-944.
- Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current
Heart Failure Reports. 2009;6:287-292.
- Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-
- Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to
guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
- Angermann, C.E., Assmus, B., Anker, S.D. et al. Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective
CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clin Res Cardiol. 107, 991–1002 (2018). doi.org/10.1007/s00392-018-1281-8.
- Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol.
- Givertz MM, Stevenson LW, Costanzo MR, et al., on behalf of the CHAMPION Trial Investigators. Pulmonary artery pressure–guided management of patients with heart
failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70:1875-86.